Georgia Institute of Technology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Georgia Institute of Technology sits in the top decile of US sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count).
Georgia Institute of Technology: 24 sponsored US clinical trials, 5 recruiting.
Georgia Institute of Technology sponsors 24 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 15 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stroke, with 4 trials.
Top-decile sponsor footprint
Georgia Institute of Technology ranks in the top decile of sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
24 total, page 1 of 1
Ankle Exoskeleton for Stroke Gait Enhancement
NCT07179627
Lower-Limb Exoskeleton Technology for Non-Ambulatory Individuals With Spinal Cord Injury
NCT07128901
tVNS During Motor Training in Older Adults
NCT06323954
Adaptive Hip Exoskeleton for Stroke Gait Enhancement
NCT05536739
Neurobiological Mechanisms of Aging and Stress on Prospective Navigation
NCT03896529
Clinical Efficacy of Exoskeleton Assistance for Individuals Post-Stroke
NCT06064604
Engaging Kids With Robotic Exoskeletons and Gamification
NCT06647082
Multimodal Differences in Effort-based Decision-Making in Depression
NCT06648460
tVNS Responsiveness Testing With Pupil Size
NCT06335199
Intent Recognition for Prosthesis Control
NCT05537792
Robotically Augmented Mental Practice
NCT04962698
The Role of Different Prefrontal Areas in Visual Metacognition
NCT04263766
Personalizing MPK Prescription
NCT06399471
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
NCT04979858
Everyday Memory Intervention
NCT04088136
TechSAge Tele Tai Chi for People Aging With Mobility Disabilities
NCT04696887
Powered Hip Exoskeleton Assistance Study
NCT03924752
American Sign Language-Accessible Diabetes Education
NCT03980808
Optimizing Ankle Exoskeleton Assistance for Walking Across the Life Span
NCT04033146
Assistive Hip Exoskeleton Study for Stroke
NCT03924765
Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)
NCT03926598
Noninvasive Vagus Nerve Stimulation (VNS) for Neuromotor Adaptations
NCT03628976
3D X-ray Motion Analysis of Ankle-foot Motion After Total Ankle Arthroplasty
NCT03575975
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
NCT01124292
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Georgia Institute of Technology pipeline
5 recruiting of 24 indexed (21% open); 15 completed (63%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Stroke (4 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Georgia Institute of Technology: open-pipeline peers nationwide
Peers matched on 24 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
Georgia Institute of Technology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 24 trials (± recruiting share)
- Acrotech Biopharma · 24 trials · 8% recruiting
- Agenus · 24 trials · 0% recruiting
- Akebia Therapeutics · 24 trials · 4% recruiting
- Blueprint Medicines Corporation · 24 trials · 25% recruiting
Sponsors near 21% open enrollment (± trial volume)
- W.L.Gore & Associates · 21% recruiting · 53 trials
- Octapharma · 21% recruiting · 43 trials
- Craig Hospital · 21% recruiting · 29 trials
- University of Colorado, Denver · 21% recruiting · 1,283 trials
Related
What to do with this Georgia Institute of Technology page
24 registered trials is a research-attention snapshot, not an endorsement of Georgia Institute of Technology or any single study.
- 5 of Georgia Institute of Technology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Stroke is the condition Georgia Institute of Technology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stroke trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Georgia Institute of Technology pipeline card: 24 registered trials from official public datasets.Report a data error.